Literature DB >> 17920285

Oxidatively modified RNA in mild cognitive impairment.

Mark A Lovell1, William R Markesbery.   

Abstract

Studies show increased oxidative damage in the brains of subjects with Alzheimer's disease (AD) and mild cognitive impairment (MCI). To determine if RNA oxidation occurs in MCI, sections of hippocampus/parahippocampal gyrus (HPG) from 5 MCI, 5 late stage AD (LAD) and 5 age-matched normal control (NC) subjects were subjected to immunohistochemistry using antibodies against 8-hydroxyguanine (8-OHG) and 1-N2-propanodeoxyguanosine (NPrG). Confocal microscopy showed 8-OHG and NPrG immunostaining was significantly (p<0.05) elevated in MCI and LAD HPG compared with NC subjects and was predominately associated with neurons identified using the MC-1 antibody that recognizes conformational alterations of tau, which are associated with early neurofibrillary tangle formation. Pretreating sections with RNase or DNase-I showed immunostaining for both adducts was primarily associated with RNA. In addition, levels of both adducts in MCI were comparable to those measured in LAD, suggesting RNA oxidation may be an early event in the pathogenesis of neuron degeneration in AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920285      PMCID: PMC2700659          DOI: 10.1016/j.nbd.2007.07.030

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  44 in total

1.  Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome.

Authors:  A Nunomura; G Perry; K Hirai; G Aliev; A Takeda; S Chiba; M A Smith
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 2.  Carbonyl toxicology and Alzheimer's disease.

Authors:  Matthew J Picklo; Thomas J Montine; Venkataraman Amarnath; M Diana Neely
Journal:  Toxicol Appl Pharmacol       Date:  2002-11-01       Impact factor: 4.219

3.  Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

Authors:  G A Jicha; R Bowser; I G Kazam; P Davies
Journal:  J Neurosci Res       Date:  1997-04-15       Impact factor: 4.164

4.  Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue.

Authors:  Xinli Liu; Mark A Lovell; Bert C Lynn
Journal:  Anal Chem       Date:  2005-09-15       Impact factor: 6.986

5.  Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin.

Authors:  A Banerjee; M C Roach; P Trcka; R F Ludueña
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

6.  Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4.

Authors:  K S Montine; S J Olson; V Amarnath; W O Whetsell; D G Graham; T J Montine
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

7.  Oxidative damage is the earliest event in Alzheimer disease.

Authors:  A Nunomura; G Perry; G Aliev; K Hirai; A Takeda; E K Balraj; P K Jones; H Ghanbari; T Wataya; S Shimohama; S Chiba; C S Atwood; R B Petersen; M A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2001-08       Impact factor: 3.685

8.  Conformational change as one of the earliest alterations of tau in Alzheimer's disease.

Authors:  C L Weaver; M Espinoza; Y Kress; P Davies
Journal:  Neurobiol Aging       Date:  2000 Sep-Oct       Impact factor: 4.673

Review 9.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

10.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

View more
  43 in total

Review 1.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

Review 2.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 3.  Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Hyoung-gon Lee; George Perry; Xiongwei Zhu; Rudy J Castellani; Mark A Smith
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 4.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

Review 5.  Antioxidants in the canine model of human aging.

Authors:  Amy L S Dowling; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

6.  The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons.

Authors:  Akihiko Nunomura; Toshio Tamaoki; Nobutaka Motohashi; Masao Nakamura; Daniel W McKeel; Massimo Tabaton; Hyoung-Gon Lee; Mark A Smith; George Perry; Xiongwei Zhu
Journal:  J Neuropathol Exp Neurol       Date:  2012-03       Impact factor: 3.685

7.  Intrastrand G-U cross-links generated by the oxidation of guanine in 5'-d(GCU) and 5'-r(GCU).

Authors:  Conor Crean; Nicholas E Geacintov; Vladimir Shafirovich
Journal:  Free Radic Biol Med       Date:  2008-07-23       Impact factor: 7.376

8.  The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial.

Authors:  A M Alavi Naeini; I Elmadfa; A Djazayery; M Barekatain; M R Aghaye Ghazvini; M Djalali; A Feizi
Journal:  Eur J Nutr       Date:  2013-12-11       Impact factor: 5.614

Review 9.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.